These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

372 related articles for article (PubMed ID: 12615954)

  • 1. Pharmacogenetics of anticancer drug sensitivity in non-small cell lung cancer.
    Danesi R; de Braud F; Fogli S; de Pas TM; Di Paolo A; Curigliano G; Del Tacca M
    Pharmacol Rev; 2003 Mar; 55(1):57-103. PubMed ID: 12615954
    [TBL] [Abstract][Full Text] [Related]  

  • 2. Pharmacogenomics in non-small-cell lung cancer chemotherapy.
    Danesi R; Pasqualetti G; Giovannetti E; Crea F; Altavilla G; Del Tacca M; Rosell R
    Adv Drug Deliv Rev; 2009 May; 61(5):408-17. PubMed ID: 19292993
    [TBL] [Abstract][Full Text] [Related]  

  • 3. [Advanced lung cancer: progress in individualized therapy].
    Bischoff A
    MMW Fortschr Med; 2009 May; 151(21):20. PubMed ID: 19537631
    [No Abstract]   [Full Text] [Related]  

  • 4. Pharmacogenetics for individualized cancer chemotherapy.
    Efferth T; Volm M
    Pharmacol Ther; 2005 Aug; 107(2):155-76. PubMed ID: 15890408
    [TBL] [Abstract][Full Text] [Related]  

  • 5. Treatment of non-small-cell lung cancer and pharmacogenomics: where we are and where we are going.
    Rosell R; Cuello M; Cecere F; Santarpia M; Reguart N; Felip E; Taron M
    Curr Opin Oncol; 2006 Mar; 18(2):135-43. PubMed ID: 16462182
    [TBL] [Abstract][Full Text] [Related]  

  • 6. Retinoblastoma deficiency increases chemosensitivity in lung cancer.
    Zagorski WA; Knudsen ES; Reed MF
    Cancer Res; 2007 Sep; 67(17):8264-73. PubMed ID: 17804741
    [TBL] [Abstract][Full Text] [Related]  

  • 7. Pharmacogenetics of anticancer drugs in non-Hodgkin lymphomas.
    Loni L; Del Tacca M; Danesi R
    Br J Cancer; 2001 Nov; 85(10):1425-31. PubMed ID: 11720423
    [TBL] [Abstract][Full Text] [Related]  

  • 8. [Pharmacogenetics of anticancer drugs].
    de Chaisemartin L; Loriot MA
    Pathol Biol (Paris); 2005 Mar; 53(2):116-24. PubMed ID: 15708657
    [TBL] [Abstract][Full Text] [Related]  

  • 9. Genomic-wide cDNA microarray screening to correlate gene expression profile with chemoresistance in patients with advanced lung cancer.
    Oshita F; Ikehara M; Sekiyama A; Hamanaka N; Saito H; Yamada K; Noda K; Kameda Y; Miyagi Y
    J Exp Ther Oncol; 2004 Jul; 4(2):155-60. PubMed ID: 15500010
    [TBL] [Abstract][Full Text] [Related]  

  • 10. Evolution of therapy decision-making process for advanced non-small cell lung cancer.
    Gebbia V; Mancuso G; Lombardi L; Maiello E
    Oncology; 2009; 77 Suppl 1():97-102. PubMed ID: 20130437
    [TBL] [Abstract][Full Text] [Related]  

  • 11. Personalized cancer therapy with selective kinase inhibitors: an emerging paradigm in medical oncology.
    McDermott U; Settleman J
    J Clin Oncol; 2009 Nov; 27(33):5650-9. PubMed ID: 19858389
    [TBL] [Abstract][Full Text] [Related]  

  • 12. The role of pharmacogenetics in adjuvant treatment of non-small cell lung cancer.
    Danesi R; Pasqualetti G; Giovannetti E; Del Tacca M
    J Thorac Oncol; 2007 May; 2(5 Suppl):S27-30. PubMed ID: 17457227
    [TBL] [Abstract][Full Text] [Related]  

  • 13. [Frontier of mycobacterium research--host vs. mycobacterium].
    Okada M; Shirakawa T
    Kekkaku; 2005 Sep; 80(9):613-29. PubMed ID: 16245793
    [TBL] [Abstract][Full Text] [Related]  

  • 14. Overview of molecular testing in non-small-cell lung cancer: mutational analysis, gene copy number, protein expression and other biomarkers of EGFR for the prediction of response to tyrosine kinase inhibitors.
    John T; Liu G; Tsao MS
    Oncogene; 2009 Aug; 28 Suppl 1():S14-23. PubMed ID: 19680292
    [TBL] [Abstract][Full Text] [Related]  

  • 15. Molecular pathology and pharmacogenomics in Alzheimer's disease: polygenic-related effects of multifactorial treatments on cognition, anxiety and depression.
    Cacabelos R
    Methods Find Exp Clin Pharmacol; 2007 Jul; 29 Suppl A():1-91. PubMed ID: 17957277
    [TBL] [Abstract][Full Text] [Related]  

  • 16. Pharmacogenomics in breast cancer: current trends and future directions.
    Wajapeyee N; Somasundaram K
    Curr Opin Mol Ther; 2004 Jun; 6(3):296-301. PubMed ID: 15264432
    [TBL] [Abstract][Full Text] [Related]  

  • 17. Expression of class III {beta}-tubulin is predictive of patient outcome in patients with non-small cell lung cancer receiving vinorelbine-based chemotherapy.
    Sève P; Isaac S; Trédan O; Souquet PJ; Pachéco Y; Pérol M; Lafanéchère L; Penet A; Peiller EL; Dumontet C
    Clin Cancer Res; 2005 Aug; 11(15):5481-6. PubMed ID: 16061864
    [TBL] [Abstract][Full Text] [Related]  

  • 18. [Pharmacogenetics and pharmacogenomics of cancers].
    Robert J
    Pathol Biol (Paris); 2004 Jul; 52(6):332-7. PubMed ID: 15261376
    [TBL] [Abstract][Full Text] [Related]  

  • 19. Pharmacogenomics in cancer treatment defining genetic bases for inter-individual differences in responses to chemotherapy.
    Ansari M; Krajinovic M
    Curr Opin Pediatr; 2007 Feb; 19(1):15-22. PubMed ID: 17224657
    [TBL] [Abstract][Full Text] [Related]  

  • 20. Polymorphisms in XRCC1 and XPG and response to platinum-based chemotherapy in advanced non-small cell lung cancer patients.
    Sun X; Li F; Sun N; Shukui Q; Baoan C; Jifeng F; Lu C; Zuhong L; Hongyan C; YuanDong C; Jiazhong J; Yingfeng Z
    Lung Cancer; 2009 Aug; 65(2):230-6. PubMed ID: 19157633
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 19.